AI model improves recurrence risk stratification in HR-positive, HER2-negative breast cancer
An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk stratification in hormone receptor (HR)-positive, HER2-negative breast cancer